Core Viewpoint - Innovent Biologics is set to present clinical data for its bispecific antibodies and ADC molecules at the ASCO Annual Meeting 2025, highlighting advancements in cancer treatment, particularly with IBI363 and IBI343 [1][2] Group 1: Clinical Presentations - IBI363 has three indications accepted for oral presentations: melanoma, colorectal cancer (CRC), and non-small cell lung cancer (NSCLC), showcasing the attention on PD-1-based immunotherapy [2] - The Phase 1b data of IBI343 in pancreatic cancer will also be presented, reinforcing its potential in a challenging therapeutic area [2] - The presentations are scheduled between May 30 and June 3, 2025, in Chicago, Illinois [1] Group 2: Presentation Details - IBI363's efficacy and safety results in advanced acral and mucosal melanoma will be presented on May 31, 2025 [3] - The efficacy and safety of IBI363 in advanced colorectal cancer will be discussed on June 1, 2025 [4] - IBI363's application in advanced immunotherapy-treated NSCLC will be presented on June 3, 2025 [4] Group 3: Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for various diseases, including cancer [12] - The company has launched 15 products and has multiple assets in various stages of clinical trials, indicating a robust pipeline [12] - Innovent collaborates with over 30 global healthcare companies, enhancing its research and development capabilities [12]
Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting